External reports (aggregated public sources), Value Investors Club

Value Investors Club

Value Investors Club (.com) is an exclusive online investment club where top investors share their best ideas. Content available at the above link/PDF preview is an external article authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External reports (aggregated public sources)

Equity Bottom-Up

Key points<ul><li>RLMD is a biotech company with a high-stakes binary outcome in 2024 for their antidepressant, REL-1017</li><li>Despite previous phase 3 trial failures, the drug has a validated mechanism of action and promising phase 2 data, leading to a $1.1B valuation</li><li>The stock is undervalued and presents a compelling investment opportunity with significant upside potential, especially through underpriced options for exposure to the outcome in mid-2024</li></ul>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Key pointsRLMD is a biotech company with a high-stakes binary outcome in 2024 for their antidepressant, REL-1017Despite previous phase 3 trial failures, the drug has a validated mechanism of action and promising phase 2 data, leading to a $1.1B valuationThe stock is undervalued and presents a compelling investment opportunity with significant upside potential, especially through underpriced options for exposure to the outcome in mid-2024This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Relmada Therapeutics Inc (RLMD) - Wednesday, Nov 29, 2023